Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.56 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6373731 | 0.93 | AQP1 (0.47) | AQP1PTGS2EGFRPSMB5ERAP1 | |
| SCHEMBL6368102 | 0.86 | AQP1 (0.40) | AQP1PPARAPPARGCAPN1MME | |
| SCHEMBL4596608 | 0.85 | MMEL1 (0.39) | AQP1PTGS2EGFRPSMB5CAPN1 | |
| SCHEMBL4595337 | 0.83 | PTGS2 (0.38) | AQP1PTGS2EGFRPSMB5CAPN1 | |
| SCHEMBL4595205 | 0.81 | AQP1 (0.37) | AQP1MME | |
| SCHEMBL4596666 | 0.81 | AQP1 (0.36) | AQP1SHMT1PTGS2MME | |
| SCHEMBL4220793 | 0.80 | MME (0.40) | AQP1PSMB5CAPN1MME | |
| SCHEMBL6374679 | 0.79 | AQP1 (0.38) | AQP1PTGS2EGFRCAPN1 | |
| SCHEMBL4235061 | 0.78 | AQP1 (0.65) | AQP1SHMT1 | |
| SCHEMBL4233585 | 0.77 | AQP1 (0.39) | AQP1PSMB5MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | AQP1 2290/4885SHMT1 1715/4885PTGS2 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.